ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Gilead strikes deal with microbiome specialist Second Genome

by Michael McCoy
April 10, 2020 | APPEARED IN VOLUME 98, ISSUE 14

 

Gilead Sciences will pay Second Genome $38 million as part of a deal to identify biomarkers associated with clinical response in up to five Gilead drugs under development for inflammation, fibrosis, and other diseases. In addition, the firms will seek new targets and drug candidates for inflammatory bowel disease. Gilead says the agreement, which could bring Second Genome $300 million in additional milestone payments, advances its commitment to inflammatory disease research.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment